ArticleFrontiers in human neuroscience2024
Method for assessing visual saliency in children with cerebral/cortical visual impairment using generative artificial intelligence.
Article in Frontiers in human neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Validity and Reliability of the CVI Range for Clinical Research: Baseline and One-Year Results.Ophthalmology science · 2026Article
- Generative Artificial Intelligence-Enabled Saliency Analysis of Eye Tracking in Cerebral/Cortical Visual Impairment (SET-CVI).Ophthalmology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cerebral/cortical visual impairment (CVI) is a leading cause of pediatric visual impairment in the United States and other developed countries, and is increasingly diagnosed in developing nations due to improved care and survival of children who are born premature or have other risk factors for CVI. Despite this, there is currently no objective, standardized method to quantify the diverse visual impairments seen in children with CVI who are young and developmentally delayed. We propose a method that combines eye tracking and an image-based generative artificial intelligence (AI) model (SegCLIP) to assess higher- and lower-level visual characteristics in children with CVI. We will recruit 40 CVI participants (aged 12 months to 12 years) and 40 age-matched controls, who will watch a series of images on a monitor while eye gaze position is recorded using eye tracking. SegCLIP will be prompted to generate saliency maps for each of the images in the experimental protocol. The saliency maps (12 total) will highlight areas of interest that pertain to specific visual features, allowing for analysis of a range of individual visual characteristics. Eye tracking fixation maps will then be compared to the saliency maps to calculate fixation saliency values, which will be assigned based on the intensity of the pixel corresponding to the location of the fixation in the saliency map. Fixation saliency values will be compared between CVI and control participants. Fixation saliency values will also be correlated to corresponding scores on a functional vision assessment, the CVI Range-CR. We expect that fixation saliency values on visual characteristics that require higher-level processing will be significantly lower in CVI participants compared to controls, whereas fixation saliency values on lower-level visual characteristics will be similar or higher in CVI participants. Furthermore, we anticipate that fixation saliency values will be significantly correlated to scores on corresponding items on the CVI Range-CR. Together, these findings would suggest that AI-enabled saliency analysis using eye tracking can objectively quantify abnormalities of lower- and higher-order visual processing in children with CVI. This novel technique has the potential to guide individualized interventions and serve as an outcome measure in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.